Suchen und Finden




Nur ebooks mit Firmenlizenz anzeigen:


Oral Pharmacotherapy for Male Sexual Dysfunction - A Guide to Clinical Management

von: Gregory A. Broderick

Humana Press, 2007

ISBN: 9781592598717 , 464 Seiten

Format: PDF

Kopierschutz: Wasserzeichen

Windows PC,Mac OSX Apple iPad, Android Tablet PC's

Preis: 149,79 EUR


  • Clinical Forensic Medicine - A Physician's Guide
    Cardiovascular Disease in the Elderly
    Obstetric Anesthesia Handbook
    Information Technology Solutions for Healthcare
    Creatine and Creatine Kinase in Health and Disease
    Promoting Health for Working Women
    Dental Pathology - A Practical Introduction
    Forensic Pathology Reviews Vol 2
  • Pharmacotherapy of Diabetes: New Developments - Improving Life and Prognosis for Diabetic Patients
    Living with Coronary Disease
    Dose Finding in Drug Development
    Sudden Deaths in Custody
    Surgical Treatment of Hilar and Intrahepatic Cholangiocarcinoma
    Color Atlas of Strabismus Surgery - Strategies and Techniques
    Drugs Compromising Male Sexual Health
    Dynamic Regression Models for Survival Data

Mehr zum Inhalt

Oral Pharmacotherapy for Male Sexual Dysfunction - A Guide to Clinical Management


For the generation that reached sexual maturity in the 1960s, the 'pill' became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought 'this will change everything' and it clearly has-changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.